METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBF AND RUNX1 PROTEINS
申请人:The U.S.A. as represented by the Secretary,
Department of Health and Human Services
公开号:EP2685985B1
公开(公告)日:2016-08-31
US9446048B2
申请人:——
公开号:US9446048B2
公开(公告)日:2016-09-20
[EN] METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFß AND RUNX1 PROTEINS<br/>[FR] MÉTHODES DE TRAITEMENT DE LA LEUCÉMIE ET DE TROUBLES À MÉDIATION PAR LES PROTÉINES CBF? ET RUNX1
申请人:US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVIC
公开号:WO2012125787A1
公开(公告)日:2012-09-20
A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits CBFβ and RUNX1 binding in the subject, thereby treating the CBF leukemia.
Improved synthesis of 2-amino-5-chlorophenyl-2′-pyrrylketone, a key intermediate in the synthesis of HIV Tat-antagonists
作者:Masami Okabe、Ruen-Chu Sun
DOI:10.1016/0040-4020(94)01053-3
日期:1995.2
that of a 2-methylbenzoxazinone. The title compound was prepared from 5-chloroanthranilic acid via the 2-phenylbenzoxazinone in 92% overall yield. This method was also successfully applied to the synthesis of 2-aminobenzophenones.